Clinical trial · Observational
Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about conical features and treatment outcomes of each subtype should be accumulated to establish treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma was from small case series of single institute. Furthermore, as novel drugs were developed for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were treated with those novel drugs are especially required because their outcomes may reflect the outcomes of currently available treatments. Thus, a multinational, multicenter prospective registry study is needed to provide information useful for establishing treatment strategies for T-cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin T-cell Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prospective Registry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- non-Hodgkin T-cell Lymphoma
- interventionNames
- Other: Prospective Registry
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5 years
Secondary outcomes (2)
- measure
- Overall response rate to primary treatment and salvage treatment
- timeFrame
- 5 years
- measure
- Progression-free survival
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically diagnosed Mature T-cell non-Hodgkin lymphoma based on the World Health Organization classification 2008 * Newly diagnosed patients without a previous treatment history for T-cell lymphoma or relapsed/refractory T-cell lymphoma patients * Age ≥19 years * Written informed consent Exclusion Criteria: * Hodgkin lymphoma * non-Hodgkin B-cell lymphoma * Immature non-Hodgkin T-cell lymphoma: Precursor T-lymphoblastic lymphoma/leukemia * Not understanding informed consent
References
Publications (0)
Data not yet available